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Purpose: To evaluate genes involved in homocysteine metabolism as secondary risk factors for pseudoexfoliation
syndrome (PXFS) and the associated glaucoma (PXFG).
Methods: One hundred eighty-six unrelated patients with PXFS, including 140 patients with PXFG and 127 unrelated
control subjects were recruited from the Massachusetts Eye and Ear Infirmary. All the patients and controls were Caucasian
of European ancestry. Seventeen tag SNPs from 5 genes (methylenetetrahydrofolate reductase [MTHFR], methionine
synthase [MTR], methionine synthase reductase [MTRR], methylenetetrahydrofolate dehydrogenase [MTHFD1], and
cystathionine  β-synthase  [CBS])  were  genotyped.  Single-SNP  association  was  analyzed  using  Fisher’s  exact  test
(unconditional) or logistic regression after conditioning on the effects of age and three  LOXL1 SNPs (rs1048661,
rs3825942, and rs2165241). Interaction analysis was performed between the homocysteine and LOXL1 SNPs using logistic
regression. Haplotype analysis and the set-based test were used to test for association of individual genes. Multiple
comparisons were corrected using the Bonferroni method.
Results: One SNP (rs8006686) in MTHFD1 showed a nominally significant association with PXFG (p=0.015, OR=2.23).
None of the seventeen SNPs tested were significantly associated with PXFS or PXFG after correcting for multiple
comparisons (Bonferroni corrected p>0.25). After controlling for the effects of age and three associated LOXL1 SNPs,
none of the seventeen tested SNPs were associated with PXFS (p>0.12). No significant interaction effects on PXFS were
identified between the homocysteine and LOXL1 SNPs (p>0.06). Haplotype analysis and the set-based test did not find
significant association of individual genes with PXFS (p>0.23 and 0.20, respectively).
Conclusions: Five genes that are critical components of the homocysteine metabolism pathway were evaluated as
secondary factors for PXFS and PXFG. Our results suggest that these genes are not significant risk factors for the
development of these conditions.
Pseudoexfoliation  syndrome  (PXFS)  is  a  common
condition characterized by the deposition of microfibrillar
material throughout the eye. The composition of the PXFS-
related material, although not completely defined, appears to
be a complex glycoprotein structure containing elements of
basement membranes and the elastic fiber system [1]. The
biologic processes that cause this material to accumulate in
ocular structures are not known. In eyes with PXFS, fibrillar
material  is  found  throughout  the  anterior  segment  and  is
typically evident on the lens capsule and in the angle where it
may impede the flow of aqueous humor through the trabecular
outflow pathways [2]. Over 50% of individuals with PXFS
develop  high-pressure  glaucoma  (PXFG)  which  may  be
associated with rapidly progressive optic nerve degeneration
[3].
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Pseudoexfoliation  syndrome  and  the  associated
glaucoma appear to be genetically complex. Twin studies and
reports  of  familial  aggregation  demonstrated  significant
heritability  but  not  a  clearly  defined  inheritance  pattern,
suggesting  complex  or  multifactorial  inheritance  [4-6].  A
genome-wide  scan  using  a  large  Finnish  family  indicated
potential linkage to multiple chromosome regions including
18q,  2q,  17q,  and  19q  [7].  Recently,  a  genome-wide
association study identified significant association of three
SNPs  (rs1048661,rs3825942,  and  rs2165241)  in  the  lysyl
oxidase-like 1 (LOXL1) gene with PXFS and PXFG in patients
from  Iceland  and  Sweden  [8].  This  association  has  been
replicated in our study of a USA clinic-based population with
broad ethnic diversity [9] and in other studies using ethnic
populations of Caucasian [10-16], Indian [17], and Japanese
[18-22]. These results demonstrate that LOXL1 is a major gene
associated with PXFS and PXFG.
Two of the highly associated LOXL1 SNPs are missense
changes  in  exon  1  (rs3825942,  G153D  and  rs1048661,
R141L), however, it is not yet known if these variants are
biologically causative or are in linkage disequilibrium with
other gene variants that are biologically active. The G153D
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2484risk allele (G) frequency is very high in PXFG patients in most
of the populations studied (92%–99%), but is also prevalent
in control samples, with a frequency of over 65% in many
populations [8-22]. In addition, in the Australian population
the frequency of the rs3825942 risk allele is much higher than
the disease prevalence, indicating a reduction in penetrance
compared  to  the  USA  and  European  populations  [14].
Collectively, these results suggest that additional genetic and/
or environmental factors that are potentially additive and/or
protective could influence the development of this complex
disorder [23].
Previous  reports  have  indicated  that  homocysteine  is
moderately elevated in aqueous humor, tear fluid, and serum
plasma of patients with PXFS and PXFG [24-26]. It has been
proposed that mild elevations of homocysteine may contribute
to  the  increased  vascular  risk  that  has  been  observed  in
patients  with  PXFS,  which  includes  aneurysms  of  the
abdominal  aorta  [27].  It  is  well  recognized  that
hyperhomocysteinemia  is  associated  with  vascular
abnormalities  [28],  and  the  modest  elevations  reported  in
PXFS patients could initiate vascular damage that could be
further compromised by abnormal LOXL1 activity. Variants
in genes that regulate the homocysteine pathways could be
responsible for the observed elevations of homocysteine and
these  may  be  additive  genetic  factors  that  influence  the
development of the syndrome. The purpose of this study was
to  evaluate  5  genes  encoding  enzymes  that  regulate
homocysteine  metabolism  as  secondary  factors  that  could
contribute to PXFS and PXFG.
METHODS
Patients  and  control  subjects:  One  hundred  eighty-six
patients  with  PXFS  were  recruited  from  the  Glaucoma
Consultation  Service  at  the  Massachusetts  Eye  and  Ear
Infirmary, Boston, MA. Patients with PXFS were identified
by the presence of the characteristic fibrillar material on the
lens  capsule  or  pupillary  margin.  Patients  with  iris
transillumination defects without the presence of the fibrillar
material were not identified as pseudoexfoliation patients, or
controls. Of the 186 patients with PXFS, 140 had glaucoma
(PXFG) and 46 did not (PXFNG). Glaucoma was defined as:
intraocular pressure >22 mmHg in both eyes on two occasions
or intraocular pressure >19 mmHg in both eyes on treatment
with two or more glaucoma medications; evidence of optic
nerve damage in both eyes; and visual field defects consistent
with optic nerve damage and characteristic for glaucoma in at
least one eye. One hundred twenty-seven control subjects
were  recruited  from  the  Comprehensive  Ophthalmology
Service at the Massachusetts Eye and Ear Infirmary, Boston,
MA. Control subjects had no evidence of pseudoexfoliation
or glaucoma after clinical exam. The average age of the PXFS
patients  was  75.  Because  of  the  age-dependence  of  the
pseudoexfoliation syndrome, only controls older than age 60
were used for this analysis with an average age of 72. This
study population (cases and controls) included only Caucasian
participants of European ancestry. Fifty-nine percent of the
patients  were  female  with  41%  male,  while  51%  of  the
controls were female and 49% were male. This study adhered
to the tenets of the Declaration of Helsinki and has been
reviewed and approved by the Institutional Review Board of
the Massachusetts Eye and Ear Infirmary. Informed consent
was obtained from all patients and controls.
Gene polymorphisms and genotyping: Five genes that encode
proteins that are involved in homocysteine metabolism were
investigated in this study (Figure 1). These genes are MTHFR
(methylenetetrahydrofolate  reductase),  MTR  (methionine
synthase), MTRR (methionine synthase reductase), MTHFD1
(methylenetetrahydrofolate  dehydrogenase),  and  CBS
(cystathionine  β-synthase).  Tag  SNPs  corresponding  to
linkage  disequilibrium  (LD)  blocks  were  selected  using
Haploview (version 4.1) [29] according to the HapMap data
(release 23a) from the CEU population. The minimum minor
allele frequency for checking markers was set to 0.01. Three
or 4 tag SNPs were selected for each gene to capture the
majority of alleles at r2 greater than 0.8 across the whole gene
including the 5′UTR and 3′UTR (Table 1). Each LD block was
captured by 1 or 2 SNPs although not all alleles in each gene
were captured. Genotyping was performed either by TaqMan
assays (Applied Biosystems [ABI], Foster City, CA) or by
direct sequencing. For the TaqMan assays, oligonucleotide
primers  were  ordered  from  ABI  (assay  by  demand)  and
performed according to the manufacturer’s instructions. For
direct  sequencing,  products  from  PCR  amplification  were
purified and sequenced using BigDye® chemistries (ABI) and
an automated genetic analyzer (model 3100; ABI). Sequence
data was analyzed using Vector NTI suite (version 8).
Statistical analysis: Statistical analyses were performed using
PLINK (version 1.04) [30]. Hardy–Weinberg equilibrium was
assessed by the χ2 test. Linkage disequilibrium was measured
using  r2.  Initial  single-SNP  association  analysis  was
performed using the Fisher's exact test. Multivariable analysis
of individual SNPs was performed using logistic regression
models. The additive effects model was applied to analysis of
allele dosage in which the genotypes AA, AB, BB were coded
as 0, 1, 2, respectively, where A represents the minor allele
and B represents the common allele. After controlling for the
effects  of  age  and  three  significant  LOXL1  SNPs
(rs1048661,rs3825942, and rs2165241), individual SNPs in
the homocysteine genes were analyzed for association with
PXFS using logistic regression. Interaction analysis of pair-
wise SNPs between the homocysteine SNPs and the LOXL1
SNPs was performed by including an interaction term in the
logistic regression models. Haplotype analysis and the set-
based test were used to test for association of individual genes.
Haplotype frequencies were estimated using the standard E-
M algorithm and tested using the χ2 test. The omnibus p-values
for haplotype analysis were obtained from the omnibus test.
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these single SNP statistics is significant after permutation,
which  is  particularly  suited  to  large-scale  candidate  gene
studies [31]. The empirical p values of the set-based test were
obtained  by  a  permutation  of  10,000  times  of  phenotype
labels.  Multiple  comparisons  were  corrected  using  the
Bonferroni method.
RESULTS
Single-SNP  association  analysis:  Seventeen  SNPs  in  five
genes were analyzed for association with PXFS, PXFG, and
PXFNG  (Table  1).  All  of  these  SNPs  followed  Hardy–
Weinberg equilibrium in both cases and controls (p>0.05).
The selected SNPs were not in strong LD (r2<0.26), which is
consistent with the HapMap data from the CEU population.
Only one SNP, rs8006686 in MTHFD1, showed a marginally
significant  association  with  PXFS  (p=0.015;  OR=2.07,
95%CI: 1.16, 3.71) and PXFG (p=0.015; OR=2.23, 95%CI:
1.19, 4.16). However, none of these SNPs were significantly
associated with PXFS, PXFG or PXFNG after correcting for
multiple comparisons (Bonferroni corrected p>0.25; Table 2).
After  controlling  for  the  effects  of  age  and  the  three
significant  LOXL1  SNPs  (rs1048661,  rs3825942,  and
rs2165241), logistic regression analysis also showed that none
of the SNPs in the homocysteine genes were associated with
PXFS (p>0.12; Table 3). No significant interaction effects on
PXFS were found between the homocysteine SNPs and the
LOXL1 SNPs (p>0.06; data not shown).
Gene-based  association  analysis:  Haplotype  association
analysis  of  all  the  tag  SNPs  in  each  gene  revealed  no
association of individual genes with PXFS (omnibus p>0.23;
Table 4). Set-based association tests also did not identify
significant  association  of  individual  genes  with  PXFS
(empirical p>0.04, Bonferroni corrected p>0.20; Table 4).
DISCUSSION
Recent studies suggest that LOXL1 is a major gene associated
with PXFS/PXFG, contributing to the majority of cases in
Figure 1. Homocysteine metabolic pathways. Products of the enzymatic pathways are shown in rectangles, co-factors are shown in circles,
and enzymes are in text. The genes coding for the enzymes included in this study are shown as underlined text. Abbreviations: B12, vitamin B12;
BHMT, betaine-homocysteine methyltransferase; CBS, cystathionine beta synthase; DHF, dihydrofolate; DHFR, dihydrofolate reductase;
dTMP,  thymidine  monophosphate;  dUMP,  uridine  monophosphate;  FAD,  flavin  adenine  dinucleotide;  GLY,  glycine;  MTHFD1,
trifunctional methylenetetrahydrofolate dehydrogenase, cyclohydrolase, synthase; MTHFR, methylenetetrahydrofolate reductase; MTR, 5-
methyltetrahydrofolate-homocysteine  methyltransferase;  MTRR,  5-methyltetrahydrofolate-homocysteine  methyltransferase  reductase;
MT, methyl transferase; SAH, S-adenosylhomocysteine hydrolase; SER, serine; THF, tetrahydrofolate; TS, thymidylate synthase; 5-CH3-
THF,  5-methyl  tetrahydrofolate;  5,10-CH2=THF,  methylene  tetrahydrofolate;  5,10=CH2-THF,  methenyl  tetrahydrofolate;  10-CHO-
THF, 10-formyl tetrahydrofolate.
Molecular Vision 2008; 14:2484-2491 <http://www.molvis.org/molvis/v14/a286> © 2008 Molecular Vision
2486most populations [8-22]. However, the high prevalence of the
rs3825942 risk allele in control populations, and the apparent
variable  penetrance  of  the  condition  in  some  populations
suggest that additional genetic factors and/or environmental
exposures  could  be  involved  in  the  development  of  this
complex disease. As moderate hyperhomocysteinemia has
been  repeatedly  described  in  PXFS  and  PXFG  patients
[24-26],  we  evaluated  the  genes  that  code  for  proteins
involved  in  homocysteine  metabolism  as  candidates  for
secondary factors contributing to this disease.
Multiple reports have indicated that patients with PXFS
have mild elevations of homocysteine in serum plasma, as
well  as  aqueous  humor  and  tear  fluid  [24-26].  As  the
association of hyperhomocysteinemia with vascular disease
has been well documented [28], and ocular and systemic blood
vessels in PXFS can be abnormal [32], we hypothesized that
elevated  homocysteine  caused  by  variant  forms  of  genes
TABLE 1. CHARACTERISTICS AND GENOTYPE COUNTS OF THE 17 SNPS IN 5 HOMOCYSTEINE GENES.
Gene SNP Chr Position (bp)
Codon
change
Genotype count (AA/AB/BB)*
PXFS PXFG PXFNG Controls
MTHFR rs1801131 1 11777063 E429A 13/29/37 11/20/26 2/9/11 9/19/22
MTHFR rs1801133 1 11778965 A222V 10/41/33 7/31/23 3/10/10 7/22/21
MTHFR rs17037396 1 11784634 intron 0/15/71 0/13/46 0/2/25 0/17/73
MTR rs12096955 1 235055726 intron 14/40/31 10/28/21 4/12/10 12/39/40
MTR rs2229274 1 235056807 D294N 0/3/80 0/2/59 0/1/21 0/4/53
MTR rs1805087 1 235115123 D919G 6/57/121 6/44/88 0/13/33 6/38/74
MTRR rs326122 5 7929611 intron 2/29/53 1/20/37 1/9/16 5/22/62
MTRR rs1532268 5 7931179 S202L 7/37/37 6/26/26 1/11/11 11/25/18
MTRR rs161870 5 7931192 L206L 17/27/20 11/22/14 6/5/6 10/19/11
MTRR rs162036 5 7938959 R377K 4/20/63 4/13/43 0/7/20 3/20/68
MTHFD1 rs8006686 14 63938424 intron 5/27/55 2/23/35 3/4/20 0/21/70
MTHFD1 rs2236225 14 63978598 R653Q 34/96/51 24/71/42 10/25/9 30/52/35
MTHFD1 rs11627387 14 63993730 intron 7/31/45 4/23/30 3/8/15 8/32/50
CBS rs2124459 21 43348783 intron 16/43/29 9/39/23 7/4/6 14/40/37
CBS rs1801181 21 43353685 A360A 21/75/77 13/60/58 8/15/19 14/43/49
CBS rs5742905 21 43356253 I278T 1/32/151 1/25/112 0/7/39 2/10/96
CBS rs234715 21 43361464 intron 4/29/55 3/25/43 1/4/12 5/30/54
The asterisk indicates that “A” represents the minor allele and “B” represents the common allele.
TABLE 2. SINGLE-SNP ASSOCIATION OF HOMOCYSTEINE GENES WITH PXFS, PXFG AND PXFNG.
Gene SNP
Minor
allele
Minor allele frequency p value*
PXFS PXFG             PXFNG               Controls           PXFS            PXFG            PXFNG
MTHFR rs1801131 C 0.348 0.368 0.295 0.370 0.79 1.00 0.45
MTHFR rs1801133 T 0.363 0.369 0.348 0.360 1.00 1.00 1.00
MTHFR rs17037396 T 0.087 0.110 0.037 0.094 0.85 0.70 0.26
MTR rs12096955 T 0.400 0.407 0.385 0.346 0.32 0.33 0.62
MTR rs2229274 A 0.018 0.016 0.023 0.035 0.45 0.43 1.00
MTR rs1805087 G 0.188 0.203 0.141 0.212 0.47 0.83 0.16
MTRR rs326122 G 0.196 0.190 0.212 0.180 0.78 0.88 0.69
MTRR rs1532268 T 0.315 0.328 0.283 0.435 0.053 0.10 0.10
MTRR rs161870 A 0.477 0.468 0.500 0.488 0.89 0.88 1.00
MTRR rs162036 A 0.161 0.175 0.130 0.143 0.66 0.52 1.00
MTHFD1 rs8006686 C 0.213 0.225 0.185 0.115 0.015 0.015 0.25
MTHFD1 rs2236225 T 0.453 0.434 0.489 0.479 0.56 0.33 0.62
MTHFD1 rs11627387 G 0.271 0.272 0.269 0.267 1.00 1.00 1.00
CBS rs2124459 C 0.426 0.401 0.471 0.374 0.33 0.65 0.13
CBS rs1801181 T 0.338 0.328 0.369 0.335 1.00 0.92 0.59
CBS rs5742905 C 0.092 0.098 0.076 0.065 0.28 0.25 0.81
CBS rs234715 G 0.210 0.218 0.176 0.225 0.80 1.00 0.65
The asterisk indicates that p values were obtained from Fisher’s exact test when compared to controls. The Bonferroni corrected
significance level was 0.003 (0.05/17).
Molecular Vision 2008; 14:2484-2491 <http://www.molvis.org/molvis/v14/a286> © 2008 Molecular Vision
2487coding  for  key  enzymes  involved  in  homocysteine
metabolism could contribute to the PXFS. Defects in LOXL1
can also compromise the elastic structure of blood vessels
[33],  and  that  the  combined  effects  of  elevated  serum
homocysteine and LOXL1 deficiency could synergistically
contribute to vascular compromise. Abnormalities of ocular
vasculature,  especially  blood  vessels  in  the  iris  could  be
related to the deposition of the microfibrillar material that is
characteristic of the disease process. Previous studies have
failed  to  show  an  association  between  homocysteine
metabolism genes and PXFS [34-39], however these studies
have  evaluated  only  the  well  studied  common  C677T
polymorphism (rs1801133) in MTHFR, a central regulator of
homocysteine levels. In this study we took a broader approach
and evaluated 5 genes involved in homocysteine metabolism,
including the MTHFR gene. We did not find any significant
association between any of the homocysteine genes and PXFS
and/or PXFG in this present study.
TABLE 3. SINGLE-SNP ASSOCIATION OF HOMOCYSTEINE GENES WITH PXFS AFTER CONTROLLING FOR THE EFFECTS OF AGE AND
3 LOXL1 SNPS.
Gene SNP                             Minor allele p value* OR (95% CI)*
MTHFR rs1801131 C 0.95 0.98 (0.49, 1.96)
MTHFR rs1801133 T 0.55 0.79 (0.37, 1.70)
MTHFR rs17037396 T 0.81 0.89 (0.33, 2.40)
MTR rs12096955 T 0.23 1.43 (0.80, 2.54)
MTR rs2229274 A 0.55 0.52 (0.06, 4.41)
MTR rs1805087 G 0.69 0.90 (0.52, 1.55)
MTRR rs326122 G 0.95 1.02 (0.50, 2.07)
MTRR rs1532268 T 0.82 1.09 (0.50, 2.38)
MTRR rs161870 A 0.46 0.74 (0.33, 1.65)
MTRR rs162036 A 0.91 0.96 (0.49, 1.90)
MTHFD1 rs8006686 C 0.21 1.62 (0.76, 3.45)
MTHFD1 rs2236225 T 0.77 0.93 (0.59, 1.47)
MTHFD1 rs11627387 G 0.24 0.68 (0.36, 1.29)
CBS rs2124459 C 0.71 1.13 (0.61, 2.10)
CBS rs1801181 T 0.49 1.18 (0.74, 1.89)
CBS rs5742905 C 0.12 2.07 (0.84, 5.14)
CBS rs234715 G 0.57 0.80 (0.36, 1.74)
The asterisk indicates that p values and odds ratios (OR) with 95% confidence intervals (CI) were obtained from logistic
regression  analysis of single-SNP association of homocysteine genes with PXFS after controlling for the effects of age and the 3
LOXL1  SNPs (rs1048661, rs3825942, and rs2165241).
TABLE 4. GENE-BASED ASSOCIATION OF HOMOCYSTEINE GENES WITH PXFS.
Gene SNPs
p value
Haplotype test* Set-based test#
MTHFR rs1801131, 
rs1801133, rs17037396
0.97 1.00
MTR rs12096955 , 
rs2229274, rs1805087
0.68 1.00
MTRR rs326122 , 
rs1532268, rs161870, rs162036
0.85 0.19
MTHFD1 rs8006686 , 
rs2236225, rs11627387
0.30 0.04
CBS rs2124459, 
rs1801181, rs5742905, rs234715
0.23 1.00
The asterisk indicates that the p values were obtained from the omnibus haplotype test using PLINK (version 1.04) [30] and the
the sharp (hash mark) indicates that the p values were obtained from the set-based test by a permutation of 10,000 times using
PLINK (version 1.04) [30]. The Bonferroni corrected significance level was 0.01 (0.05/5).
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of homocysteine to cystathionine. The CBS c.844_845ins68
mutation has been associated with increased CBS enzyme
activity and decreased homocysteine levels [40,41], and has
been hypothesized to have a protective effect against vascular
thromboembolic  disease  [42].  We  initially  sequenced  a
sample  of  100  patients  with  PXFS  and  100  controls  and
observed that another CBS variant, rs5742905 (I278T), was
in  complete  linkage  disequilibrium  with  c.844_845ins68
(r2=1.0). We therefore considered rs5742905 as a surrogate
for c.844_845ins68 and only genotyped rs5742905 in our
subsequent samples using TaqMan assays. In our population,
we did not find any association of rs5742905 with PXFS or
PXFG, and so did the c.844_845ins68 mutation.
As age and LOXL1 variants are two known major risk
factors for PXFS and PXFG, we analyzed the association
between SNPs in homocysteine metabolism genes and PXFS
and PXFG using logistic regression after controlling for the
effects of age and the LOXL1 variants. The MTHFD1 SNP
rs8006686  was  marginally  associated  with  PXFG  before
correction  for  multiple  comparisons  (p=0.015;  Table  2).
However, this association disappeared after controlling for the
effects of age and the LOXL1 variants (p=0.21; Table 3). To
increase the statistical power to identify a possible association,
we further analyzed our data using haplotype analysis and the
set-based test, both of which are gene-based tests where all
SNPs in a gene are analyzed together. The set-based test is
particularly suited to large-scale candidate gene studies [31].
This method selects the best set of SNPs whose mean statistic
is significant, leading to the inference that the entire set of
SNPs might be interacting in some way to increase disease
risk, or else that they are all contributing independently to
disease risk. In the present study, both haplotype analysis and
the  set-based  test  did  not  find  any  significant  association
between the homocysteine genes and PXFS or PXFG (Table
4), in agreement with the logistic regression analysis of single
SNPs  in  the  homocysteine  genes  after  controlling  for  the
effects of age and the LOXL1 variants (Table 3).
We estimated that the present study had 86% of power to
detect a moderate genetic effect (genotypic relative risk of 2.0
for Aa and 4.0 for AA, given an additive risk model) [43].
However, this study had only 40% of the power needed to
detect a mild genetic effect (genotypic relative risk of 1.5 for
Aa and 2.25 for AA, given an additive risk model). In addition,
since we used tag SNPs to capture the majority of the variants
in each gene, it is possible that we might have missed other
variants in these genes associated with the disease. Further
large-scale studies and resequencing of the whole genes are
warranted to confirm our findings.
Dietary  factors  that  are  important  regulators  of
homocysteine  metabolism  have  also  been  shown  to  be
abnormal in PXFS and PXFG patients including low levels of
B6, B12, and folate [44]. It is possible that diets that are low
in these vitamins may contribute to these conditons by causing
an  elevation  of   homocysteine   levels  with  subsequent
interaction  with  the  vascular  insult  caused  by  defective
LOXL1. Although further documentation is necessary before
disease risks can be determined, individuals who are carriers
of the LOXL1 at risk genotypes should be encouraged to
maintain adequate levels of B6, B12, and folate in their diet.
In summary, five genes that code for critical components
of the homocysteine metabolism pathway were evaluated as
secondary factors for PXFS/PXFG in the present study. Our
results suggest that variants in these genes are not major risk
factors  for  the  development  of  these  conditions.  Other
important regulators of homocysteine metabolism, such as
dietary intake of B6, B12, and folate may be contributing
secondary environmental factors. Further studies searching
for  secondary  genetic  and  environmental  factors  that
contribute to PXFS and PXFG are required to gain a better
understanding  of  the  complex  etiology  of  this  important
ocular disease.
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